Bárbara Melão, MD, PhD
@bavilima
Urologist; Oncology Department @HAManaus; Former Fellow at @UrologyMSK #ASCO25 COI: https://coi.asco.org/share/JUA-U578/B%c3%a1rbara%20Mel%c3%a3o
So honored to serve as a Featured Voice for #ASCO25 among amazing colleagues ✨ Excited to share the latest data and key takeaways from the meeting @OncBrothers @yekeduz_emre @drenriquegrande @DRBakaloudiMD @realbowtiedoc @ReginaBarCar @crisbergerot @ReneeSaliby @MikeSerzanMD…
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
Another masterpiece of Aron project. Congrats all authors specially @BourlonMaite and @MatteoSantoniMD
Biggest RWD: Cabo/nivo 1st line #kidneycancer 🔴 N=333, 17 countries & 53 centers @aron_project 🟠 mFU 15.9m, mOS not reached, mPFS 33.7m 🟢 ORR 58%, CR 6% 🟣 Poor prognosis: ECOG, sarcomatoid, brain & bone mets 🔵 ≥ G3 AE 37% (Hypertension & HFS) frontiersin.org/journals/oncol…
The always excellent @OncoAlert RoundUp🚨 Exercise in metastatic #ProstateCancer ✨alleviates ADT-related burdens ✨enhances immune response ✨slows disease progression REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 #OncoTwitter #UroOnc…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…
🚨 Ready to take your surgical skills to the next level? Train on hyper-realistic models in our Hands-On Program: Laparoscopic Partial Nephrectomy, endorsed by @siu_urology Learn from expert surgeons and master every step of the procedure. 🔗 Sign-up link in the first comment
New editorial in @MASCC_JSCC @NaomiTakemura discusses as #SurvOnc ⬆️ many face complex challenges Adapting #TreatableTraits model - a personalized approach: 👨⚕️clinical 🏋️♂️physical 🏃lifestyle, and ⛪️psychospiritual needs 🔗: link.springer.com/article/10.100… @DrNicolasHart…
Check out #GUARDSymposium2025 ✨‼️✨
Did you miss the #GUARDSymposium2025 ? We Have you covered🚨, here are some Great Presentations from Some of the World's TOP GU Oncologists📺 ⭐️What biomarkers are necessary in advanced urothelial carcinoma? Dr. Yves Allory Guard Symposium25 youtu.be/cwrUNwkqw3o?si… ⭐️Andrea…
#SuppOnc commentary from @CharlesJiangMD et al in @NatRevClinOncol Despite ⬆️ pt willingness, #clinicaltrial enrollment is ⬇️ (~7%) 🚧. Using the #COMB 🪮model: ⬆️ capability, opportunity, and motivation can 🦾empower #oncologists to ⬆️ enrollment. 💵🚫🔗:…
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET) thelancet.com/journals/lanon… The VIOLET phase 1/2 trial evaluated the safety of the novel radioligand therapy…
Dr @cabibbo78 has a high yield #GIonc review of #IO agents in #hpbcsm #IO has transformed treatment, ⬆️ #OS and creating new #SoC. 💉 Reviews #regimens 🤝 Discusses #synergy with chemo 🚧 Highlight unmet #needs 🔗: cancertreatmentreviews.com/article/S0305-… @OncoAlert🚨 @PallOncCoP…
Day TWO #GUARDSymposium2025 🚨 Presentation by @ProfSyedHussain One line, several options: individualization of treatment in first-line metastatic #BladderCancer @tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi @DrFelixGuerrero @malvarezmaestro @urbano_anido…
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02) out on Lancet Oncology thelancet.com/journals/lanon… In the phase 3 CONTACT-02 trial, the combination of cabozantinib (a tyrosine kinase inhibitor) and atezolizumab (a PD-L1 inhibitor) was evaluated in men with…
#ActiveSurveillance for #ProstateCancer in Göteborg-1 Trial ⏩️25 years FU ✨Failure-free survival rate at 22 yr: 68% ✨PC-specific survival rate at 25 yr: 94% ✨PC-specific survival rate at 24 yr: - 99% for very-low-risk - 92% for low-risk - 85% for intermediate-risk…
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial sciencedirect.com/science/articl… This long-term follow-up study from the GÖTEBORG-1 screening trial evaluated outcomes in 488 men with…
DAY TWO 🚨 #GUARDSymposium2025 Presentation by Dr. @AndreaNecchi 🇮🇹 NeoAdjuvant 🆚Adjuvant🆚PeriOperative Therapy for Muscle Invasive #BladderCancer @tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi @DrFelixGuerrero @malvarezmaestro @urbano_anido @JaviMolinaC @Dav_Lorente…
DAY ONE🚨 #GUARDSymposium2025 Presenting @DrIacovelli 🇮🇹 on How to Treat Patients in 2nd Line after progression to TKI+IO #KidneyCancer @tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi @DrFelixGuerrero @malvarezmaestro @urbano_anido @JaviMolinaC @Dav_Lorente @vital_hevia…
LIVE DAY 1 #GUARDSymposium2025 Presentation by Dr. Paolo Castellucci🇮🇹 on Staging of localized high risk #ProstateCancer with PET PSMA PSMA PET/CT offers significant advantages in staging high-risk prostate cancer due to its superior accuracy in detecting both nodal and…
DAY ONE🚨 #GUARDSymposium2025 Dr Gerhardt Attard 🇬🇧Presenting: To which patients should we offer systemic Treatment Intensification in Localized high risk #ProstateCancer @tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi @DrFelixGuerrero @malvarezmaestro @urbano_anido…
DAY ONE🚨 #GUARDSymposium2025 @PBarataMD 🇺🇸Presenting How to Treat Patients with #RCC who Relapse after Adjuvant Treatment #KidneyCancer @tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi @DrFelixGuerrero @malvarezmaestro @urbano_anido @JaviMolinaC @Dav_Lorente…
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration…
Wonderful talks by @bergsa83 @DrTFriedlander on UTUC & bladder Ca “tour de force”: huge progress made, we keep going on! @shilpaonc @VivekSubbiah @UrologieParis @AtishChoudhury @Prof_Nick_James @koshkin85 @easterho @BourlonMaite @bavilima @UroDocAsh @karima_oualla @JCensits
SIU-ICUD: Epidemiology of #ProstateCancer 2025 @SigridCarlsson @KlotzLaurence mdpi.com/2563-6499/6/3/…
Another study confirming poor prognosis in patients harboring HRR mutations
@OncoAlert Newsletter 🚨 ❗️HRR alterations in mHSPC are associated with shorter time to mCRPC REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… @wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala…